GDRX Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -12.89%, SMA50 -21.52%, SMA200 -45.51%). The stock’s 14-day RSI is 36.89 (weak momentum), while the ATR of 0.18 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -65.75% below its high and over -5.24% above its low. Average 10-day trading volume of 1.16 million shares is below the 3-month average of 2.68 million, indicating normal recent market interest.

GoodRx Holdings, Inc. generated EPS of $0.09 over the past year. Five-year average earnings growth is -17.73%. Wall Street analysts project EPS growth of 23.55% annually over the next five years. The latest quarter delivered EPS of $0.09. The next quarter is forecast at $0.10. Next year's EPS is expected at $13.27. Analyst sentiment is neutral. Analyst rating data shows there are 2 Strong Buy ratings, 3 Buy ratings, 6 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $7.00 to $2.75. The high target offers 180.0% upside. The low target suggests 10.0% downside. The mean target is $4.52. This offers 80.8% upside. GoodRx Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended February 25, 2026, missed forecasts by 0.0%. The prior quarter beat by -11.11%. Over the last six quarters, Apple has recorded several small beats. These include -11.11% in November 07, 2024.

GoodRx Holdings, Inc. has 98.58 million shares outstanding. The public float is 86.44 million shares, elevated short interest at 7.29% of float. This equals 6.37 million shares. The short ratio is 5.3 days. Institutional investors hold 71.91% of the float. Insiders own 12.67%. Abdiel Capital Management, LLC holds 8.06 million shares, Slutsky Andrew has 2.88 million shares and Wagner Scott has 182.90 thousand shares.

GoodRx Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.40. This means the shares are trading below this model’s fair value.

GoodRx Holdings, Inc. (NASDAQ:GDRX) closed at $2.50 USD, losing -$0.05 (-1.96%) from the previous close of $2.55. The stock is currently mid-range between its 52-week high and low $1.77 and $5.81. With a market capitalization of about $856.74 million, GoodRx Holdings, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.55). Key stats such as the average daily volume over the past year has been around 2.49 million shares, volume is running light vs its 52-week average. Headquartered in Santa Monica, CA, GoodRx Holdings, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Wendy Barnes, the company employs approximately 738 people and listed since September 23, 2020. GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States.

GoodRx Holdings, Inc. trades at a P/E ratio of 28.22, slightly below the S&P 500 average, with a price-to-sales ratio of 1.09 and a price-to-book ratio of 1.39 suggesting the stock is closer to book value. The P/FCF stands at 7.98, also above market averages.

Our AI price prediction model suggests that GoodRx Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.8%, with price expected at $2.57 by May 18, 2026, within a range of $2.48 to $2.66 3-Month Outlook: Projected fall of -42.4%, reaching $1.44 by July 31, 2026, with a range of $1.31 to $1.56. 1-Year Outlook: Projected gain of 8.8%, with price at $2.72 by May 04, 2027, within a range of $0.00 to $2.08.

GoodRx Holdings, Inc. (NASDAQ:GDRX) shares are flat -4.06% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows GoodRx Holdings, Inc. trading at a premium to the broader market with a P/E of 28.22. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $8.71, suggesting 248.4% upside. Our AI forecast model points to short-term strength (2.8% over two weeks), a medium-term fall (-42.4% over three months), and a longer-term gain (8.8% over one year), with expected trading ranges indicating moderate volatility.